Install
Zacks Small Cap Research coverage specifically looks to focus on small and micro-cap companies that are under followed or under valued by Wall Street.
- 38articles · 30d
- 3+ day agolatest article
- Aug 17, 2026earliest in window
- 0%with images
- 298avg words
- Economy, Business & Finance 33
- Finance & Business 25
- News 21
- Health & Wellness 10
- Medical 8
- Business & Industrial 6
- Industrial 5
- Health 4
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
CPKF Posts Another Strong Quarter with Diluted EPS Up 75% Year over Year
4+ day, 20+ hour ago (278+ words) By Ann Heffron, CFA, CPA READ THE FULL CPKF RESEARCH REPORT Chesapeake Financial (OTCQX: CPKF) produced another strong quarter with 2026 second quarter net earnings surging $2.3 million, or 74%, to $5.5 million year over year, while 2026’s second quarter diluted EPS rose $0.50, or…...
CING: Second Quarter Results
3+ week, 4+ day ago (305+ words) READ THE FULL CING RESEARCH REPORT Cingulate, Inc. (NASDAQ: CING) reported second quarter 2026 results on August 13th, 2026. During the three-month period, the company generated no revenue and recorded operating expense of $5.4 million. Since the end of the first quarter, cash balances…...
COSM Produces Stellar Quarter
3+ week, 4+ day ago (783+ words) READ THE FULL COSM RESEARCH REPORT Record Q2 Results Demonstrate Accelerating Scale We see this as an important milestone because Cosmos generated only $65.3 million of revenue during all of 2025. The current run rate suggests to us that the company's growth trajectory…...
RVPH: Patent Filed for New Formulation
3+ week, 6+ day ago (847+ words) //s27.q4cdn.com/906368049/files/pictures/2026/08172026_RVPH_1.png RVPH: Patent Filed for New Formulation Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) reported second quarter 2026 results on August 12th, 2026. Earlier this year, Reviva engaged with the FDA seeking feedback regarding a formulation change for brilaroxazine to be…...
ABEO: Zevaskyn® Launch Gains Momentum
3+ week, 6+ day ago (115+ words) READ THE FULL ABEO RESEARCH REPORT Five Patients Treated in 2Q26; 12 Patients Treated in Total Thus Far Abeona recently activated its seventh QTC at Cincinnati Children’s, while CHOP and UTMB have begun collecting patient biopsies and CHOP has already completed its…...
ICU: Continued Revenue Growth for QUELIMMUNE®
3+ week, 6+ day ago (934+ words) //s27.q4cdn.com/906368049/files/pictures/2026/08172026_ICU_1.png ICU: Continued Revenue Growth for QUELIMMUNEÃÂî YoY Revenue Growth of 82% for QUELIMMUNE SeaStar Medical Holding Corp. (NASDAQ: ICU) is increasingly validating its commercial strategy for QUELIMMUNE, as exhibited by an 82% YoY growth in…...
CTSO: CytoSorbents Future Value Drivers Support Price Target of $4.00
3+ week, 6+ day ago (127+ words) By Tom Kerr, CFA READ THE FULL CTSO RESEARCH REPORT 2nd Quarter 2026 Financial Results Based on 2nd quarter 2026 results and management commentary, we adjust our full year 2026 revenue estimate to $38.1 million and adjust our 2026 non-GAAP loss per share to ($0.22). We believe 2027 revenues…...
CRDF: Second Quarter Earnings
3+ week, 6+ day ago (1084+ words) By John Vandermosten, CFA NASDAQ: CRDF READ THE FULL CRDF RESEARCH REPORT 2Q:26 Financial Results Cardiff Oncology, Inc. (NASDAQ: CRDF) reported second quarter 2026 financial and operational results in a press release and Form 10-Q filing with the SEC on August 11th, 2026. The…...